Norepinephrine inhibits the migratory activity of pancreatic cancer cells

Experimental Cell Research

Volumn 319, Issue 12, 2013, Pages 1744-1758

  Stock, Anna Maria ^a   Powe, Desmond G ^b   Hahn, Stephan A ^c   Troost, Gabriele ^a   Niggemann, Bernd ^a   Zänker, Kurt S ^a   Entschladen, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Beta adrenergic receptors; Cell migration; Norepinephrine; Signal transduction

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; CYCLIC AMP; NORADRENALIN; PHOSPHOLIPASE C GAMMA; PROPRANOLOL; PROTEIN KINASE C ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84879605285     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.04.015     Document Type: Article

References (41)

1. Entschladen F., Zanker K.S., Powe D.G. Heterotrimeric G protein signaling in cancer cells with regard to metastasis formation. Cell Cycle 2011, 10:1086-1091.
2. Entschladen F., Drell T.L., Lang K., Joseph J., Zaenker K.S. Neurotransmitters and chemokines regulate tumour cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr. Pharm. Des. 2005, 11:403-411.
3. Drell T.L., Joseph J., Lang K., Niggemann B., Zaenker K.S., Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res. Treat. 2003, 80:63-70.
4. Lang K., Drell T.L., Lindecke A., Niggemann B., Kaltschmidt C., Zaenker K.S., Entschladen F. Induction of a metastatogenic tumour cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer 2004, 112:231-238.
5. Masur K., Niggemann B., Zanker K.S., Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001, 61:2866-2869.
6. Sloan E.K., Priceman S.J., Cox B.F., Yu S., Pimentel M.A., Tangkanangnukul V., Arevalo J.M., Morizono K., Karanikolas B.D., Wu L., Sood A.K., Cole S.W. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010, 70:7042-7052.
7. Palm D., Lang K., Niggemann B., Drell T.L., Masur K., Zaenker K.S., Entschladen F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer 2006, 118:2744-2749.
8. Barron T.I., Connolly R.M., Sharp L., Bennett K., Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J. Clin. Oncol. 2011, 29:2635-2644.
9. Melhem-Bertrandt A., Chavez-Macgregor M., Lei X., Brown E.N., Lee R.T., Meric-Bernstam F., Sood A.K., Conzen S.D., Hortobagyi G.N., Gonzalez-Angulo A.M. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2011, 29:2645-2652.
10. Powe D.G., Voss M.J., Zaenker K.S., Habashi H.O., Green A.R., Ellis I.O., Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1:628-638.
11. De Giorgi V., Grazzini M., Gandini S., Benemei S., Lotti T., Marchionni N., Geppetti P. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch. Intern. Med. 2011, 171:779-781.
12. Lemeshow S., Sorensen H.T., Phillips G., Yang E.V., Antonsen S., Riis A.H., Lesinski G.B., Jackson R., Glaser R. Beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol. Biomarkers Prev. 2011, 20:2273-2279.
13. E.S. Diaz, B.Y. Karlan, A.J. Li, Impact of beta blockers on epithelial ovarian cancer survival, Gynecol. Oncol. Epub 12 (2012), 375-378.
14. H.H. Grytli, M.W. Fagerland, S.D. Fossa, K.A. Tasken, L.L. Haheim, Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy, Prostate Epub 73 (2013), 250-260.
15. Powe D.G., Entschladen F. Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat. Rev. Clin. Oncol. 2011, 8:511-512.
16. Shah S.M., Carey I.M., Owen C.G., Harris T., Dewilde S., Cook D.G. Does beta-blocker therapy improve cancer survival: findings from a population based retrospective cohort study?. Br. J. Clin. Pharmacol. 2011, 72:157-161.
17. Palm D., Lang K., Brandt B., Zaenker K.S., Entschladen F. In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin. Cancer Biol. 2005, 15:396-404.
18. Bastian P., Lang K., Niggemann B., Zaenker K.S., Entschladen F. Myosin regulation in the migration of tumour cells and leucocytes within a three-dimensional collagen matrix. Cell. Mol. Life Sci. 2005, 62:65-76.
19. Masur K., Lang K., Niggemann B., Zanker K.S., Entschladen F. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol. Biol. Cell 2001, 12:1973-1982.
20. Joseph J., Niggemann B., Zaenker K.S., Entschladen F. The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res. 2002, 62:6467-6469.
21. Lang K., Hatt H., Niggemann B., Zaenker K.S., Entschladen F. A novel function for chemokines: downregulation of neutrophil migration. Scand. J. Immunol. 2003, 57:350-361.
22. Guo K., Ma Q., Wang L., Hu H., Li J., Zhang D., Zhang M. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol. Rep. 2009, 22:825-830.
23. Huang X.Y., Wang H.C., Yuan Z., Huang J., Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology 2012, 59:889-893.
24. Entschladen F., Drell T.L., Lang K., Masur K., Palm D., Bastian P., Niggemann B., Zaenker K.S. Analysis methods of human cell migration. Exp. Cell Res. 2005, 307:418-426.
25. Meyer A.S., Hughes-Alford S.K., Kay J.E., Castillo A., Wells A., Gertler F.B., Lauffenburger D.A. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J. Cell Biol. 2012, 197:721-729.
26. Morioka N., Tanabe H., Inoue A., Dohi T., Nakata Y. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia. Neurochem. Int. 2009, 55:226-234.
27. Lang K., Niggemann B., Zanker K.S., Entschladen F. Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int. J. Cancer 2002, 99:673-680.
28. Joseph J., Niggemann B., Zaenker K.S., Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumour cells and T lymphocytes. Cancer Immunol. Immunother. 2004, 53:723-728.
29. Bastian P., Balcarek A., Altanis C., Strell C., Niggemann B., Zaenker K.S., Entschladen F. The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett. 2009, 274:218-224.
30. Meisenhelder J., Suh P.G., Rhee S.G., Hunter T. Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. Cell 1989, 57:1109-1122.
31. Murphy L.O., Cluck M.W., Lovas S., Otvos F., Murphy R.F., Schally A.V., Permert J., Larsson J., Knezetic J.A., Adrian T.E. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br. J. Cancer 2001, 84:926-935.
32. Wang Y., Wu J., Wang Z. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol. Biol. Cell 2006, 17:2267-2277.
33. Yokoyama M., Ebert M., Funatomi H., Friess H., Buchler M., Johnson G., Korc M. Amphiregulin is a potent mitogen in human pancreatic-cancer cells-correlation with patient survival. Int. J. Oncol. 1995, 6:625-631.
34. Yokoyama M., Funatomi H., Kobrin M., Ebert M., Friess H., Buchler M., Korc M. Betacellulin, a member of the epidermal growth-factor family, is overexpressed in human pancreatic-cancer. Int. J. Oncol. 1995, 7:825-829.
35. Lemoine N.R., Lobresco M., Leung H., Barton C., Hughes C.M., Prigent S.A., Gullick W.J., Kloppel G. The erbB-3 gene in human pancreatic cancer. J. Pathol. 1992, 168:269-273.
36. Ellenrieder V., Hendler S.F., Ruhland C., Boeck W., Adler G., Gress T.M. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer 2001, 93:204-211.
37. Zaenker K.S., Entschladen F. Paving roads for new drugs in oncology. Recent Pat. Anticancer Drug Discov. 2009, 4:137-145.
38. Rocha-Lima C.M., Raez L.E. Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P T 2009, 34:554-564.
39. Liu H., Xu J., Zhou L., Yun X., Chen L., Wang S., Sun L., Wen Y., Gu J. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011, 71:7547-7557.
40. Wang D.S., Chen D.L., Ren C., Wang Z.Q., Qiu M.Z., Luo H.Y., Zhang D.S., Wang F.H., Li Y.H., Xu R.H. ABO blood group, hepatitis B viral infection, and risk of pancreatic cancer. Int. J. Cancer 2011, 131:461-468.
41. J. Nieto, M.L. Grossbard, P. Kozuch, Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13 (2008), 562-576.